

Titolo	A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hematopoietic Stem Cell Transplantation.
Codice studio	ALL2418
Patologia:	Leucemia linfoblastica acuta
Tipo di Studio:	interventistico con farmaco
Tipologia	no profit
Fase:	NA
Principali criteri di inclusione:	- ALL must have >20% blasts in bone marrow at the time of diagnosis - Blasts at the diagnosis or in any timepoint had to be CD22+. - To have a measurable BCR-ABL1 fusion transcript (cohort 1) or a measurable IG/TCR specific rearrangement (cohort 2) - To have any measurable MRD positivity after at least 3 months of therapy for Ph+ ALL, or the failure of at least 2nd line TKI (cohort 1) 2 courses of therapy for Ph- ALL (cohort 2) And to not have more than 5% of bone marrow blasts. - Patients has to be in 1st or 2nd complete remission.
Principali criteri di esclusione:	- Burkitt lymphoma and active CNS leukemia. - Patients who have received any investigational drug $\leq$ 4 weeks. - Patient that received during their life diagnosis of VOD or had ongoing VOD
Struttura	SCDU Ematologia e Terapie Cellulari
Contatto	Prof.ssa Daniela Cilloni daniela.cilloni@unito.it